Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1

English version České info

Recent cross-sectional analyses of HIV-1+ plasmas have indicated that broadly cross-reactive neutralizing antibody responses are developed by 10%–30% of HIV-1+ subjects. The timing of the initial development of such anti-viral responses is unknown. It is also unknown whether the emergence of these responses coincides with the appearance of antibody specificities to a single or multiple regions of the viral envelope glycoprotein (Env). Here we analyzed the cross-neutralizing antibody responses in longitudinal plasmas collected soon after and up to seven years after HIV-1 infection. We find that anti-HIV-1 cross-neutralizing antibody responses first become evident on average at 2.5 years and, in rare cases, as early as 1 year following infection. If cross-neutralizing antibody responses do not develop during the first 2–3 years of infection, they most likely will not do so subsequently. Our results indicate a potential link between the development of cross-neutralizing antibody responses and specific activation markers on T cells, and with plasma viremia levels. The earliest cross-neutralizing antibody response targets a limited number of Env regions, primarily the CD4-binding site and epitopes that are not present on monomeric Env, but on the virion-associated trimeric Env form. In contrast, the neutralizing activities of plasmas from subjects that did not develop cross-neutralizing antibody responses target epitopes on monomeric gp120 other than the CD4-BS. Our study provides information that is not only relevant to better understanding the interaction of the human immune system with HIV but may guide the development of effective immunization protocols. Since antibodies to complex epitopes that are present on the virion-associated envelope spike appear to be key components of earliest cross-neutralizing activities of HIV-1+ plasmas, then emphasis should be made to elicit similar antibodies by vaccination.

Vyšlo v časopise: Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1. PLoS Pathog 7(1): e32767. doi:10.1371/journal.ppat.1001251
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001251

Souhrn

Zdroje

1. MooreJP

CaoY

HoDD

KoupRA

1994 Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 68 5142 5155

2. TomarasGD

YatesNL

LiuP

QinL

FoudaGG

2008 Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82 12449 12463

3. LiB

DeckerJM

JohnsonRW

Bibollet-RucheF

WeiX

2006 Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80 5211 5218

4. MoorePL

GrayES

ChogeIA

RanchobeN

MlisanaK

2008 The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 82 1860 1869

5. RichmanDD

WrinT

LittleSJ

PetropoulosCJ

2003 Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100 4144 4149

6. Doria-RoseNA

KleinRM

DanielsMG

O'DellS

NasonM

2010 Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84 1631 1636

7. SatherDN

ArmannJ

ChingLK

MavrantoniA

SellhornG

2009 Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83 757 769

8. SimekMD

RidaW

PriddyFH

PungP

CarrowE

2009 Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83 7337 7348

9. StamatatosL

MorrisL

BurtonDR

MascolaJR

2009 Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15 866 870

10. DeeksSG

SchweighardtB

WrinT

GalovichJ

HohR

2006 Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80 6155 6164

11. PiantadosiA

PanteleeffD

BlishCA

BaetenJM

JaokoW

2009 Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83 10269 10274

12. van GilsMJ

EulerZ

SchweighardtB

WrinT

SchuitemakerH

2009 Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23 2405 14

13. BinleyJM

LybargerEA

CrooksET

SeamanMS

GrayE

2008 Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 11651 11668

14. LiY

SvehlaK

LouderMK

WycuffD

PhogatS

2009 Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83 1045 1059

15. NandiA

LavineCL

WangP

LipchinaI

GoepfertPA

Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396 339 348

16. ScheidJF

MouquetH

FeldhahnN

SeamanMS

VelinzonK

2009 Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 636 640

17. ShenX

ParksRJ

MontefioriDC

KirchherrJL

KeeleBF

2009 In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 83 3617 3625

18. DhillonAK

DonnersH

PantophletR

JohnsonWE

DeckerJM

2007 Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81 6548 6562

19. LiY

MiguelesSA

WelcherB

SvehlaK

PhogatA

2007 Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13 1032 1034

20. PietzschJ

ScheidJF

MouquetH

SeamanMS

BroderCC

2010 Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol 84 5032 5042

21. WalkerLM

BowleyDR

BurtonDR

2009 Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library. J Mol Biol 389 365 375

22. WalkerLM

SimekMD

PriddyF

GachJS

WagnerD

2010 A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals. PLoS Pathog 6 e1001028

23. DeeksSG

KitchenCM

LiuL

GuoH

GasconR

2004 Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104 942 947

24. Penn-NicholsonA

HanDP

KimSJ

ParkH

AnsariR

2008 Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. Virology 372 442 456

25. BinleyJM

DitzelHJ

BarbasCF3rd

SullivanN

SodroskiJ

1996 Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses 12 911 924

26. ZwickMB

JensenR

ChurchS

WangM

StieglerG

2005 Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79 1252 1261

27. ZwickMB

LabrijnAF

WangM

SpenlehauerC

SaphireEO

2001 Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75 10892 10905

28. CortiD

LangedijkJP

HinzA

SeamanMS

VanzettaF

2010 Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5 e8805

29. HioeCE

XuS

ChigurupatiP

BurdaS

WilliamsC

1997 Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 9 1281 1290

30. NelsonJD

BrunelFM

JensenR

CrooksET

CardosoRM

2007 An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 81 4033 4043

31. GrayES

MadigaMC

MoorePL

MlisanaK

Abdool KarimSS

2009 Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 83 11265 11274

32. SatherDN

StamatatosL

2010 Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 28Suppl 2 B8 12

33. GrayES

MoorePL

ChogeIA

DeckerJM

Bibollet-RucheF

2007 Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81 6187 6196

34. MillerMD

GeleziunasR

BianchiE

LennardS

HrinR

2005 A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102 14759 14764

35. NelsonJD

KinkeadH

BrunelFM

LeamanD

JensenR

2008 Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377 170 183

36. WalkerLM

PhogatSK

Chan-HuiPY

WagnerD

PhungP

2009 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 285 289

37. DooresKJ

BurtonDR

2010 Variable loop glycan dependency of the broad and potent HIV-1 neutralizing antibodies PG9 and PG16. J Virol 84 10510 21

38. DerbyNR

GrayS

WaynerE

CampoganD

VlahogiannisG

2007 Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. Virology 366 433 445

39. GornyMK

XuJ-Y

KarwowskaS

BuchbinderA

Zolla-PaznerS

1993 Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 150 635 643

40. SandersRW

VenturiM

SchiffnerL

KalyanaramanR

KatingerH

2002 The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76 7293 7305

41. ScanlanCN

PantophletR

WormaldMR

Ollmann SaphireE

StanfieldR

2002 The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J Virol 76 7306 7321

42. TrkolaA

PurtscherM

MusterT

BallaunC

BuchacherA

1996 Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 1100 1108

43. EulerZ

van GilsMJ

BunnikEM

PhungP

SchweighardtB

2010 Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 201 1045 1053

44. NurievaR

ChungY

HwangD

YangX

KangH

2008 Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29 138 149

45. ChtanovaT

TangyeS

NewtonR

FrankN

HodgeM

2004 T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 173 68 78

46. Good-JacobsonK

SzumilasC

ChenL

SharpeA

TomaykoM

2010 PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 11 535 542

47. Doria-RoseNA

KleinRM

ManionMM

O'DellS

PhogatA

2009 Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83 188 199

48. GornyMK

StamatatosL

VolskyB

ReveszK

WilliamsC

2005 Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 79 5232 5237

49. RobinsonJE

FrancoK

ElliottDH

MaherMJ

ReynaA

2010 Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol 84 3443 3453

50. BinleyJM

WrinT

KorberB

ZwickMB

WangM

2004 Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78 13232 13252

51. HerreraC

SpenlehauerC

FungMS

BurtonDR

BeddowsS

2003 Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 77 1084 1091

52. ChenL

Do KwonY

ZhouT

WuX

O'DellS

2009 Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326 1123 1127

53. PietzschJ

ScheidJF

MouquetH

KleinF

SeamanMS

2010 Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med 207 1995 2002

54. RongR

Bibollet-RucheF

MulengaJ

AllenS

BlackwellJL

2007 Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81 1350 1359

55. HarringtonPR

NelsonJA

KitrinosKM

SwanstromR

2007 Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection. J Virol 81 5413 5417

56. SagarM

WuX

LeeS

OverbaughJ

2006 Human immunodeficiency virus type 1 V1–V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80 9586 9598

57. DerbyNR

KraftZ

KanE

CrooksET

BarnettSW

2006 Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80 8745 8762

58. LiM

GaoF

MascolaJR

StamatatosL

PolonisVR

2005 Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. J Virol 79 10108 10125

59. LiM

Salazar-GonzalezJF

DerdeynCA

MorrisL

WilliamsonC

2006 Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 11776 11790

60. LongEM

RainwaterSM

LavreysL

MandaliyaK

OverbaughJ

2002 HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 18 567 576

61. BlishCA

NedellecR

MandaliyaK

MosierDE

OverbaughJ

2007 HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21 693 702